stockrow
Monday 9 November 2026
Export ABOS’s income statement to Excel — free account
Acumen Pharmaceuticals, Inc.
ABOS- EPS
- +20.3%
- Free cash flow
- +12.6%
- Total debt
- −14.3%
Quarter to September 2026, against a year earlier
0.22
0.01
+4.76%
Follow ABOS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | 2 | 1 | — | — | — | — | — | 1 | (15.4%) | — | — | — | — | |
| Gross margin, % | — | — | — | 100.00 | 100.00 | 0.00 | 0.00 | — | — | — | 0.00 | (100.0) pt | ||||||
| EBT | — | — | — | (8) | (7) | (101) | (43) | (52) | (102) | (121) | (104) | +57.6% | ||||||
| EBT margin, % | — | — | — | (465.94) | (510.10) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +465.9 pt | ||||||
| Net income | — | 0 | — | (8) | (7) | (101) | (43) | (52) | (102) | (121) | (104) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | 3.94 | 3.43 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | (18.35) | (17.48) | (5.02) | (1.06) | (1.08) | (1.71) | (2.00) | (1.54) | (30.9%) | ||||||
| Cash flow | — | — | — | (15.83) | (17.78) | (0.90) | (0.87) | (0.89) | (1.44) | (1.91) | (1.22) | (29.7%) | ||||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | (15.83) | (17.78) | (0.90) | (0.87) | (0.89) | (1.44) | (1.91) | (1.22) | (29.7%) | ||||||
| Book value | — | — | — | (26.51) | (44.37) | 11.23 | 4.65 | 5.49 | 3.03 | 1.16 | 0.48 | n/m | ||||||
| Shares, m | — | — | — | 0 | 0 | 20 | 41 | 49 | 60 | 61 | 67 | +128.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | 0.00 | 0.00 | — | — | — | — | — | 0.00 | 0.0 | |||||
| P/S | — | — | — | 6.05 | 6.05 | — | — | — | — | — | 11.08 | 6.0 | ||||||
| P/B | — | — | — | 0.00 | 0.00 | — | — | — | — | — | 0.46 | 0.0 | ||||||
| EV/Sales | — | — | — | (41.87) | (41.87) | — | — | — | — | — | (25.36) | (41.9) | ||||||
| EV/FCF | — | — | — | 5.58 | 5.58 | — | — | — | — | — | 0.41 | 5.6 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (7) | (7) | (18) | (35) | (43) | (86) | (116) | (88) | +60.3% | |||||
| Capex | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | +21.8% | ||||||
| Free cash flow | — | — | — | (7) | (7) | (18) | (35) | (43) | (86) | (116) | (88) | +60.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | 6 | 43 | 194 | 173 | 234 | 151 | 92 | 40 | +55.9% | |||||
| Net debt | — | — | — | (7) | (44) | (194) | (177) | (214) | (142) | (86) | (52) | +53.5% | ||||||
| Shareholders’ equity | — | — | — | (11) | (19) | 225 | 189 | 267 | 182 | 70 | 35 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | (209.94) | (28.31) | (73.23) | (20.08) | (20.67) | (37.27) | (67.07) | (91.28) | +142.9 pt | |||||
| ROIC | — | — | — | 0.00 | 0.00 | (39.55) | (250.76) | (71.63) | (179.60) | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | 51.22 | 48.82 | (97.40) | (20.71) | (22.98) | (45.60) | (96.20) | (162.72) | (147.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 7 | 17 | 40 | 52 | 61 | 61 | — | +54.2% | |||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2020 · latest quarter Dec 2020 · fundamentals updated 2 Nov 2026
Acumen Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics, Inc. | $18.7M | — (loss-making) | — | — | n/m | +55.74% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ABOS Acumen Pharmaceuticals, Inc. | $16.2M | — (loss-making) | — | — | n/m | +12.58% (above 0%: growing) | 0.00% | 0.00% | |
| PLUR Pluri Inc. | $15.6M | — (loss-making) | — (loss-making) | −15.83% (below 0%: shrinking) | n/m | +25.03% (above 0%: growing) | 58.51% | (1,655.52%) | Compare |
| VAXX Vaxxinity, Inc. | $15.5M | — (loss-making) | — (loss-making) | −100.23% (below 0%: shrinking) | n/m | +17.00% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ALLR Allarity Therapeutics, Inc. | $15.4M | — (loss-making) | — (loss-making) | — | n/m | +53.22% (above 0%: growing) | 100.00% | 0.00% | Compare |
| NEUP Neuphoria Therapeutics Inc. | $15.0M | — (loss-making) | — (loss-making) | −107.32% (below 0%: shrinking) | n/m | +133.86% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CTXR Citius Pharmaceuticals, Inc. | $15.0M | — (loss-making) | — | — | n/m | −60.50% (below 0%: shrinking) | 67.07% | (785.39%) | Compare |
| MRKR MARKER THERAPEUTICS, INC. | $14.9M | — (loss-making) | — (loss-making) | −51.00% (below 0%: shrinking) | n/m | −97.84% (below 0%: shrinking) | 209.68% | 0.00% | Compare |
| NCEL NewcelX Ltd. | $14.7M | — (loss-making) | — | — | n/m | −87.71% (below 0%: shrinking) | 0.00% | — | Compare |
| Median of peers | $15.2M | — | — | −75.61% | — | +21.02% | 62.79% | 0.00% |
Pay and ownership Proxy statement filed 23 April 2026
Ownership
Directors and executive officers, together
10.20%
Entities affiliated with RA Capital
29.30%
Entities affiliated with James B. Murray Jr. Revocable Trust
5.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement